During the past decade, Renal Research conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Renal Research" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Dimerix Bioscience Pty Ltd" with 2 trials sponsored, "BioAge Labs, Inc." with 1 trials sponsored, "Chinook Therapeutics U.S., Inc." with 1 trials sponsored and "Idorsia Pharmaceuticals Ltd." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Renal Research" #1 collaborator was "Iqvia Pty Ltd" with 2 trials as a collaborator, "Centessa Pharmaceuticals plc" with 1 trials as a collaborator, "Janssen Biotech, Inc." with 1 trials as a collaborator, "National Health and Medical Research Council, Australia" with 1 trials as a collaborator and "Novotech (Australia) Pty Limited" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Renal Research" are "ADPKD" (2 trials), "Autosomal Dominant Polycystic Kidney" (2 trials), "Chronic Kidney Diseases" (2 trials), "Diabetic Kidney Disease" (2 trials) and "Focal Segmental Glomerulosclerosis" (2 trials). Many other conditions were trialed in "Renal Research" in a lesser frequency.

Most popular intervention types in "Renal Research" are "Drug" (12 trials), "Other" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "BI 685509" (2 trials), "Propagermanium" (2 trials), "Aprocitentan 12.5 mg" (1 trials) and "Aprocitentan 25 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Renal Research" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Renal Research". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Renal Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Renal Research, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".